Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis

Devouassoux, Gilles; Cottin, Vincent; Lioté, H.; Marchand, Éric; Frachon, Irène; Schüller, Arthur; Bejui-Thivolet, F; Jf, Cordier

doi:10.1183/09031936.00091608

Cited by 107 publications

(83 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only one nonreversible obstructive syndrome was encountered at diagnosis (the patient with an OB pattern at CT scan). This obstructive syndrome worsened during the follow-up: the ratio residual volume/total lung capacity became .140% [7].…”

Section: To the Editorsmentioning

confidence: 99%

Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies

Hervier¹,

Uzunhan²,

Hachulla³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

Section: To the Editorsmentioning

confidence: 99%

Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies

Hervier¹,

Uzunhan²,

Hachulla³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

“…A combination of histopathological patterns may also suggest an underlying CTD (e.g. the combinations of a UIP pattern with prominent lymphocytic inflammation and lymphocytic or follicular bronchiolitis are particularly frequent in patients with rheumatoid arthritis) [1,18].…”

Section: When Should Ctd Be Suspected?mentioning

confidence: 99%

Significance of connective tissue diseases features in pulmonary fibrosis

Cottin

2013

European Respiratory Review

Self Cite

View full text Add to dashboard Cite

Interstitial lung disease (ILD) can occur in any of the connective tissue diseases (CTD) with varying frequency and severity, and an overall long-term prognosis that is less severe than that of idiopathic pulmonary fibrosis (IPF). Because ILD may be the presenting manifestation of CTD and/or the dominant manifestation of CTD, clinical extra-thoracic manifestations should be systematically considered in the diagnostic approach of ILD. When present, autoantibodies strongly contribute to the recognition and classification of the CTD. Patients with clinical extrathoracic manifestations of CTD and/or autoantibodies (especially with a high titer and/or the antibody is considered “highly specific” of an autoimmune condition), but who do not fit with established international CTD criteria may be called undifferentiated CTD or “lung-dominant CTD”. Although it remains to be determined which combination of symptoms and serologic tests best identify the subset of patients with clinically relevant CTD features, available evidence suggests that such patients may have distinct clinical and imaging presentation and may portend a distinct clinical course. However, autoantibodies alone when present in IPF patients do not seem to impact prognosis or management. Referral to a rheumatologist and multidisciplinary discussion may contribute to management of patients with undifferentiated CTD

show abstract

“…The mainstay of treatment is to discontinue the offending agent, which will occasionally result in the regression of symptoms. However, the overall prognosis is poor [67]. High-dose corticosteroids are often used, although they rarely have an impact [68].…”

Section: Lower Airway Involvementmentioning

confidence: 99%